Mduduzi S. L. Masilela

发表

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK

Nguyen H. Tran, Vidyashankara G. Iyer, Andreas C. Themistocleous, 2020, Lancet.

Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials

Nguyen H. Tran, Vidyashankara G. Iyer, Andreas C. Themistocleous, 2021, The Lancet.

Preliminary Efficacy of the NVX-CoV2373 Covid-19 Vaccine Against the B.1.351 Variant

D. Moodley, S. Madhi, V. Shinde, 2021, medRxiv.

Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant

S. Madhi, A. Sigal, T. de Oliveira, 2021, The New England Journal of Medicine.

Immunogenicity and safety of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine in people living with and without HIV-1 infection: a randomised, controlled, phase 2A/2B trial

D. Moodley, S. Madhi, V. Shinde, 2022, The Lancet HIV.

Durability of ChAdOx1 nCoV-19 (AZD1222) vaccine and hybrid humoral immunity against variants including omicron BA.1 and BA.4 6 months after vaccination (COV005): a post-hoc analysis of a randomised, phase 1b–2a trial

S. Madhi, S. Richardson, P. Moore, 2022, The Lancet Infectious Diseases.

Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in people living with and without HIV in South Africa: an interim analysis of a randomised, double-blind, placebo-controlled, phase 1B/2A trial

S. Madhi, J. Vekemans, P. Moore, 2021, The Lancet HIV.

Novavax NVX-COV2373 triggers neutralization of Omicron sub-lineages

S. Madhi, V. Shinde, U. Lalloo, 2023, Scientific Reports.

Efficacy of the NVX-CoV2373 Covid-19 Vaccine Against the B.1.351 Variant

D. Moodley, S. Madhi, V. Shinde, 2021, The New England Journal of Medicine.

Efficacy of the NVX-CoV2373 Covid-19 Vaccine Against the B.1.351 Variant

D. Moodley, S. Madhi, V. Shinde, 2021, The New England journal of medicine.

Safety and efficacy of the ChAdOx1 nCoV-19 (AZD1222) Covid-19 vaccine against the B.1.351 variant in South Africa

S. Madhi, A. Sigal, T. de Oliveira, 2021, medRxiv.

ChAdOx1 nCoV-19 (AZD1222) Covid-19 vaccine efficacy against the B.1.351 variant

S. Madhi, A. Sigal, T. de Oliveira, 2021, The New England Journal of Medicine.

Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant

S. Madhi, A. Sigal, P. Moore, 2021, The New England Journal of Medicine.